tradingkey.logo
tradingkey.logo
Suchen

Molecular Partners AG

MOLN
Zur Watchlist hinzufügen
3.980USD
+0.050+1.27%
Handelsschluss 07/02, 13:00ETKurse um 15 Minuten verzögert
149.29MMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Molecular Partners AG Unternehmen

Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

Molecular Partners AG Informationen

BörsenkürzelMOLN
Name des UnternehmensMolecular Partners AG
IPO-datumOct 22, 2014
CEOAmstutz (Patrick)
Anzahl der mitarbeiter159
WertpapierartDepository Receipt
GeschäftsjahresendeOct 22
AddresseWagistrasse 14
StadtSCHLIEREN
BörseNASDAQ OMX - NASDAQ BASIC
LandSwitzerland
Postleitzahl8952
Telefon41447557700
Websitehttps://www.molecularpartners.com/
BörsenkürzelMOLN
IPO-datumOct 22, 2014
CEOAmstutz (Patrick)

Führungskräfte von Molecular Partners AG

Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Michael Tobias Stumpp, Ph.D.
Dr. Michael Tobias Stumpp, Ph.D.
Executive Vice President - Projects, Member of the Management Board
Executive Vice President - Projects, Member of the Management Board
--
--
Dr. Patrick Amstutz, Ph.D.
Dr. Patrick Amstutz, Ph.D.
Chief Executive Officer, Executive Director, Member of the Management Board
Chief Executive Officer, Executive Director, Member of the Management Board
--
--
Mr. Steven H. (Steve) Holtzman, Ph.D.
Mr. Steven H. (Steve) Holtzman, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. William M. (Bill) Burns
Mr. William M. (Bill) Burns
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Seth D. Lewis
Mr. Seth D. Lewis
Senior Vice President - Investor Relations and Strategy
Senior Vice President - Investor Relations and Strategy
--
--
Mr. Sandip S. Kapadia, CPA
Mr. Sandip S. Kapadia, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Vito J. Palombella, Ph.D.
Dr. Vito J. Palombella, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Michael Vasconcelles, M.D.
Dr. Michael Vasconcelles, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Agnete B. Fredriksen, Ph.D.
Dr. Agnete B. Fredriksen, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Dominik Hoechli, M.D.
Dr. Dominik Hoechli, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Michael Tobias Stumpp, Ph.D.
Dr. Michael Tobias Stumpp, Ph.D.
Executive Vice President - Projects, Member of the Management Board
Executive Vice President - Projects, Member of the Management Board
--
--
Dr. Patrick Amstutz, Ph.D.
Dr. Patrick Amstutz, Ph.D.
Chief Executive Officer, Executive Director, Member of the Management Board
Chief Executive Officer, Executive Director, Member of the Management Board
--
--
Mr. Steven H. (Steve) Holtzman, Ph.D.
Mr. Steven H. (Steve) Holtzman, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. William M. (Bill) Burns
Mr. William M. (Bill) Burns
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Seth D. Lewis
Mr. Seth D. Lewis
Senior Vice President - Investor Relations and Strategy
Senior Vice President - Investor Relations and Strategy
--
--
Mr. Sandip S. Kapadia, CPA
Mr. Sandip S. Kapadia, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Molecular Partners AG?

Die fünf größten Anteilseigner von Molecular Partners AG sind: Dr. Michael Tobias Stumpp, Ph.D.

Wie viele Institutionen halten Anteile an Molecular Partners AG (MOLN)?

Mit Stand vom 2026Q1 halten 14 Institutionen Anteile an Molecular Partners AG, mit einem Gesamtmarktwert von etwa 3.59M, was 9.60% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -12188.00 gestiegen.